Follicular Lymphoma in China: Systematic Evaluation of Follicular Lymphoma Prognostic Models.
clinical characteristics
follicular lymphoma
immunology
lymphocyte/monocyte ratio
prognosis
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
12
2021
accepted:
31
03
2022
entrez:
15
4
2022
pubmed:
16
4
2022
medline:
16
4
2022
Statut:
epublish
Résumé
To systematically evaluate the baseline characteristics, tumour microenvironment indicators such as the lymphocyte/monocyte ratio (LMR) and treatment response (POD24) as prognostic predictors of follicular lymphoma (FL) among Chinese patients. We retrospectively analysed 112 FL patients from 2000 to 2017, whose pathology grading included 1-3a. Absolute lymphocyte and monocyte counts were determined by cell blood counting. The Kaplan-Meier method was used to analyse the influence of prognostic predictors on progression-free survival (PFS) and overall survival (OS). Multivariate analysis was conducted using the Cox proportional risk model. The long-term survival of Chinese FL patients (median PFS, 74.8 months) was slightly better than that of patients in foreign countries. Among several prognostic models, the Follicular Lymphoma International Prognostic Index (FLIPI) score had a significant effect on both PFS and OS, while there were no independent prognostic predictors. Patients with LMR ≤3.6, ALC ≤0.6*10 This study is a systematic prognostic evaluation based on Chinese clinical data. We found a new factor, the LMR, that could independently predict prognosis compared with FLIPI or FLIPI2.
Identifiants
pubmed: 35422658
doi: 10.2147/CMAR.S349193
pii: 349193
pmc: PMC9005237
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1385-1393Informations de copyright
© 2022 Li et al.
Déclaration de conflit d'intérêts
The authors report no potential conflicts of interest in this work.
Références
Adv Ther. 2017 Oct;34(10):2232-2273
pubmed: 28983798
Lancet Oncol. 2015 Sep;16(9):1111-1122
pubmed: 26256760
Ann Oncol. 2017 Dec 1;28(12):3109
pubmed: 28327933
Blood. 2018 Jul 5;132(1):49-58
pubmed: 29666118
Zhonghua Xue Ye Xue Za Zhi. 2020 Jul 14;41(7):537-544
pubmed: 32810959
J Clin Oncol. 2009 Sep 20;27(27):4555-62
pubmed: 19652063
Haematologica. 2019 Feb;104(2):338-346
pubmed: 30237271
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Nat Rev Dis Primers. 2019 Dec 12;5(1):83
pubmed: 31831752
Blood. 2016 Jun 9;127(23):2804-8
pubmed: 26994147
Leukemia. 2015 Mar;29(3):668-76
pubmed: 25151959
Am J Hematol. 2013 Dec;88(12):1062-7
pubmed: 23940056
Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e91-e97
pubmed: 28918104
Anal Cell Pathol (Amst). 2019 Dec 16;2019:8586354
pubmed: 31934533
BMJ Open. 2017 Nov 3;7(11):e017904
pubmed: 29101140